Anselamimab

安赛埃单抗

Report date: 2023/03/07 20:00:45

Base Information

Drug NameAnselamimab
Drug Alias NameChimeric fibril reactive monoclonal antibody 11-1F4Fibril-reactive monoclonal antibody 11-1F4CAEL-10111-1F4mAb 11-1F4 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionSerum amyloid A protein inhibitors
TargetsSerum amyloid A protein
Therapy Area/IndicationsAmyloidosisImmunoglobulin Light-chain Amyloidosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCaelum Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlexion Pharmaceuticals IncAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsAmyloidosisImmunoglobulin Light-chain Amyloidosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A